SLC5A2 and chronic kidney disease: Because of the design of the current trial, recent large randomized controlled trials have demonstrated that SGLT2 inhibitors can slow CKD progression and death from renal or cardiovascular causes among people with CKD, with or without type 2 diabetes29–31.